To print this article, all you need is to be registered or login on Mondaq.com.
Introduction Johnson&Johnson ) applied
in June 2019 to the Turkish Competition Authority
(
TCA ) and asked the
Competition Board (
Board ) to
assess whether Johnson&Johnson s contemplated Warehouse
Sale Agreement for Human Medicine
(
Agreement ) falls within the
protective cloak of the Block Exemption Communiqué No.
2002/2 on Vertical Agreements (
Communiqué
No. 2002/2 ) or, if not, satisfies the
conditions for an individual exemption as per Article 5 of the Law
No. 4054 on the Protection of the Competition
(
Law No. 4054 ).
The Agreement sought to establish a quantitative
1
selective distribution system whereby nine pharmaceutical
To print this article, all you need is to be registered or login on Mondaq.com.
The Nagoya Protocol is a global agreement, supplementary to the
Convention on Biological Diversity, which regulates the fair and
equitable sharing of benefits arising from the utilisation of
genetic resources and traditional knowledge associated with them
among the user and provider countries (parties), thereby
contributing to the conservation and sustainability of biological
diversity.
Although it was drafted in 2010 and signed between 2011 and
2012, it only entered into force on October 12, 2014, 90 days after
the fiftieth instrument of ratification was deposited. The Protocol
has 125 members and 127 ratifications (Montenegro and Oman are
To print this article, all you need is to be registered or login on Mondaq.com.
On February 2, 2021, Precision NanoSystems, Inc.
( PNI ) announced that it had received a contribution of
$25.1 million through the Government of Canada s Strategic
Innovation Fund (SIF).
This contribution will support a $50.2 million project to
establish a biomanufacturing centre in Vancouver dedicated to the
production of ribonucleic acid lipid nanoparticle vaccines and
genetic medicines. The centre will support the Government of
Canada s national biomanufacturing strategy to expand
production capacity of critical medicines for the prevention and
treatment of diseases such as COVID-19.
PNI is a global leader in ushering in the next wave of genetic
To print this article, all you need is to be registered or login on Mondaq.com.
New EU rules under chemicals and waste legislation require
manufacturers and suppliers of products to provide information to a
centralized EU database. These rules may also affect the medical
devices industry.
SCIP database
Since 5 January 2021, a new obligation to notify the European
Chemicals Agency ( ECHA ) applies to suppliers of
articles containing substances of very high concern
( SVHCs ) in a concentration above 0,1 % weight by weight
(w/w). The obligation is established under the revised Waste Framework Directive 2008/98/EC
( WFD ) which cross-references Regulation (EC) 1907/2006 concerning the